|
1
|
Chouliara Z, Kearney N, Stott D,
Molassiotis A and Miller M: Perceptions of older people with cancer
of information, decision making and treatment: A systematic review
of selected literature. Ann Oncol. 15:1596–1602. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Soubeyran P, Fonck M, Blanc-Bisson C,
Blanc JF, Ceccaldi J, Mertens C, Imbert Y, Cany L, Vogt L, Dauba J,
et al: Predictors of early death risk in older patients treated
with first-line chemotherapy for cancer. J Clin Oncol.
30:1829–1834. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kenis C, Bron D, Libert Y, Decoster L, Van
Puyvelde K, Scalliet P, Cornette P, Pepersack T, Luce S,
Langenaeken C, et al: Relevance of a systematic geriatric screening
and assessment in older patients with cancer: Results of a
prospective multicentric study. Ann Oncol. 24:1306–1312. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aaldriks AA, Maartense E, le Cessie S,
Giltay EJ, Verlaan HA, van der Geest LG, Kloosterman-Boele WM,
Peters-Dijkshoorn MT, Blansjaar BA, van Schaick HW and Nortier JW:
Predictive value of geriatric assessment for patients older than 70
years, treated with chemotherapy. Crit Rev Oncol Hematol.
79:205–212. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhong R, Han B and Zhong H: A prospective
study of the efficacy of a combination of autologous dendritic
cells, cytokine-induced killer cells, and chemotherapy in advanced
non-small cell lung cancer patients. Tumour Biol. 35:987–994. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gammaitoni L, Giraudo L, Leuci V,
Todorovic M, Mesiano G, Picciotto F, Pisacane A, Zaccagna A, Volpe
MG, Gallo S, et al: Effective activity of cytokine-induced killer
cells against autologous metastatic melanoma including cells with
stemness features. Clin Cancer Res. 19:4347–4358. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang J, Wu C and Lu B: Cytokine-induced
killer cells promote antitumor immunity. J Transl Med. 11:832013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hontscha C, Borck Y, Zhou H, Messmer D and
Schmidt-Wolf IG: Clinical trials on CIK cells: First report of the
international registry on CIK cells (IRCC). J Cancer Res Clin
Oncol. 137:305–310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Turksma AW, Coupé VM, Shamier MC, Lam KL,
de Weger VA, Belien JA, van den Eertwegh AJ, Meijer GA, Meijer CJ
and Hooijberg E: Extent and Location of Tumor-Infiltrating
Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome
to Adjuvant Active Specific Immunotherapy. Clin Cancer Res.
22:346–356. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saito H, Ando S, Morishita N, Lee KM,
Dator D, Dy D, Shigemura K, Adhim Z, Nibu K, Fujisawa M and
Shirakawa T: A combined lymphokine-activated killer (LAK) cell
immunotherapy and adenovirus-p53 gene therapy for head and neck
squamous cell carcinoma. Anticancer Res. 34:3365–3370.
2014.PubMed/NCBI
|
|
11
|
Huang J, Li C, Wang Y, Lv H, Guo Y, Dai H,
Wicha MS, Chang AE and Li Q: Cytokine-induced killer (CIK) cells
bound with anti-CD3/anti-CD133 bispecific antibodies target
CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol.
149:156–168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang J, Zhu L, Wei J, Liu L, Yin Y, Gu Y
and Shu Y: The effects of cytokine-induced killer cells for the
treatment of patients with solid tumors: A clinical retrospective
study. J Cancer Res Clin Oncol. 138:1057–1062. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu XC, Yang B, Yu RL, Chi XH, Tuo S, Tuo
CW, Zhu HL, Wang Y, Jiang CG, Fu XB, et al: Clinical study of
autologous cytokine-induced killer cells for the treatment of
elderly patients with diffuse large B-cell lymphoma. Cell Biochem
Biophys. 62:257–265. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao D, Li C, Xie X, Zhao P, Wei X, Sun W,
Liu HC, Alexandrou AT, Jones J, Zhao R and Li JJ: Autologous tumor
lysate-pulsed dendritic cell immunotherapy with cytokine-induced
killer cells improves survival in gastric and colorectal cancer
patients. PLoS One. 9:e938862014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao P, Bu X, Wei X, Sun W, Xie X, Li C,
Guo Q, Zhu D, Wei X and Gao D: Dendritic cell immunotherapy
combined with cytokine-induced killer cells promotes skewing toward
Th2 cytokine profile in patients with metastatic non-small cell
lung cancer. Int Immunopharmacol. 25:450–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang L, Ren B, Li H, Yu J, Cao S, Hao X
and Ren X: Enhanced antitumor effects of DC-activated CIKs to
chemotherapy treatment in a single cohort of advanced
non-small-cell lung cancer patients. Cancer Immunol Immunother.
62:65–73. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Castiglia S, Mareschi K, Labanca L,
Lucania G, Leone M, Sanavio F, Castello L, Rustichelli D, Signorino
E, Gunetti M, et al: Inactivated human platelet lysate with
psoralen: A new perspective for mesenchymal stromal cell production
in Good Manufacturing Practice conditions. Cytotherapy. 16:750–763.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
De Angelis R, Sant M, Coleman MP,
Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H,
Ardanaz E, et al: Cancer survival in Europe 1999–2007 by country
and age: Results of EUROCARE-5-a population-based study. Lancet
Oncol. 15:23–34. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Couzin-Frankel J: Breakthrough of the year
2013. Cancer immunotherapy. Science. 342:1432–1433. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li H, Wang C, Yu J, Cao S, Wei F, Zhang W,
Han Y and Ren XB: Dendritic cell-activated cytokine-induced killer
cells enhance the anti-tumor effect of chemotherapy on non-small
cell lung cancer in patients after surgery. Cytotherapy.
11:1076–1083. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang X, Yu W, Li H, Yu J, Zhang X, Ren X
and Cao S: Can the dual-functional capability of CIK cells be used
to improve antitumor effects? Cell Immunol. 287:18–22. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Price JD, Hotta-Iwamura C, Zhao Y,
Beauchamp NM and Tarbell KV: DCIR2+ cDC2 DCs and Zbtb32 restore
CD4+ T cell tolerance and inhibit diabetes. Diabetes. 64:3521–3531.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schmeel LC, Schmeel FC, Coch C and
Schmidt-Wolf IG: Cytokine-induced killer (CIK) cells in cancer
immunotherapy: Report of the international registry on CIK cells
(IRCC). J Cancer Res Clin Oncol. 141:839–849. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mao Q, Li L, Zhang C, Sun Y, Liu S and Cui
S: Clinical effects of immunotherapy of DC-CIK combined with
chemotherapy in treating patients with metastatic breast cancer.
Pak J Pharm Sci. 28:(Suppl 3). S1055–S1058. 2015.
|
|
25
|
Wang S and Wang Z: Efficacy and safety of
dendritic cells co-cultured with cytokine-induced killer cells
immunotherapy for non-small-cell lung cancer. Int Immunopharmacol.
28:22–28. 2015. View Article : Google Scholar : PubMed/NCBI
|
